Screening in asymptomatic SDHx mutation carriers: added value of ¹⁸F-FDG PET/CT at initial diagnosis and 1-year follow-up |
journalArticle |
2015 |
Lepoutre-Lussey, C.; Caramella, C.; Bidault, F.; Déandreis, D.; Berdelou, A.; Al Ghuzlan, A.; Hartl, D.; Borget, I.; Gimenez-Roqueplo, A. P.; Dumont, F.; Deschamps, F.; Nascimento, C.; Lumbroso, J.; Guillaud Bataille, M.; Schlumberger, M.; Baudin, E.; Leboulleux, S. |
Scoring of tumor-infiltrating lymphocytes: From visual estimation to machine learning |
journalArticle |
2018 |
Klauschen, F.; Müller, K. R.; Binder, A.; Bockmayr, M.; Hägele, M.; Seegerer, P.; Wienert, S.; Pruneri, G.; de Maria, S.; Badve, S.; Michiels, S.; Nielsen, T. O.; Adams, S.; Savas, P.; Symmans, F.; Willis, S.; Gruosso, T.; Park, M.; Haibe-Kains, B.; Gallas, B.; Thompson, A. M.; Cree, I.; Sotiriou, C.; Solinas, C.; Preusser, M.; Hewitt, S. M.; Rimm, D.; Viale, G.; Loi, S.; Loibl, S.; Salgado, R.; Denkert, C. |
Sarcopenia is Associated with Chemotherapy Toxicity in Patients Undergoing Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis from Colorectal Cancer |
journalArticle |
2016 |
Chemama, S.; Bayar, M. A.; Lanoy, E.; Ammari, S.; Stoclin, A.; Goere, D.; Elias, D.; Raynard, B.; Antoun, S. |
Sarcopenia is Associated with Chemotherapy Toxicity in Patients Undergoing Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis from Colorectal Cancer |
journalArticle |
2016 |
Chemama, S.; Bayar, M. A.; Lanoy, E.; Ammari, S.; Stoclin, A.; Goere, D.; Elias, D.; Raynard, B.; Antoun, S. |
Safety, tolerability and antitumour activity of LY2780301 (p70S6K/AKT inhibitor) in combination with gemcitabine in molecularly selected patients with advanced or metastatic cancer: a phase IB dose escalation study |
journalArticle |
2017 |
Angevin, E.; Cassier, P. A.; Italiano, A.; Goncalves, A.; Gazzah, A.; Terret, C.; Toulmonde, M.; Gravis, G.; Varga, A.; Parlavecchio, C.; Paci, A.; Poinsignon, V.; Soria, J. C.; Drubay, D.; Hollebecque, A. |
Safety, tolerability and antitumour activity of LY2780301 (p70S6K/AKT inhibitor) in combination with gemcitabine in molecularly selected patients with advanced or metastatic cancer: a phase IB dose escalation study |
journalArticle |
2017 |
Angevin, E.; Cassier, P. A.; Italiano, A.; Goncalves, A.; Gazzah, A.; Terret, C.; Toulmonde, M.; Gravis, G.; Varga, A.; Parlavecchio, C.; Paci, A.; Poinsignon, V.; Soria, J. C.; Drubay, D.; Hollebecque, A. |
Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination |
journalArticle |
2016 |
Boutros, C.; Tarhini, A.; Routier, E.; Lambotte, O.; Ladurie, F. L.; Carbonnel, F.; Izzeddine, H.; Marabelle, A.; Champiat, S.; Berdelou, A.; Lanoy, E.; Texier, M.; Libenciuc, C.; Eggermont, A. M.; Soria, J. C.; Mateus, C.; Robert, C. |
Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination |
journalArticle |
2016 |
Boutros, C.; Tarhini, A.; Routier, E.; Lambotte, O.; Ladurie, F. L.; Carbonnel, F.; Izzeddine, H.; Marabelle, A.; Champiat, S.; Berdelou, A.; Lanoy, E.; Texier, M.; Libenciuc, C.; Eggermont, A. M.; Soria, J. C.; Mateus, C.; Robert, C. |
Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease |
journalArticle |
2018 |
Danlos, F. X.; Voisin, A. L.; Dyevre, V.; Michot, J. M.; Routier, E.; Taillade, L.; Champiat, S.; Aspeslagh, S.; Haroche, J.; Albiges, L.; Massard, C.; Girard, N.; Dalle, S.; Besse, B.; Laghouati, S.; Soria, J. C.; Mateus, C.; Robert, C.; Lanoy, E.; Marabelle, A.; Lambotte, O. |
Robotic Prophylactic Nipple-Sparing Mastectomy with Immediate Prosthetic Breast Reconstruction: A Prospective Study |
journalArticle |
2018 |
Sarfati, B.; Struk, S.; Leymarie, N.; Honart, J. F.; Alkhashnam, H.; Tran de Fremicourt, K.; Conversano, A.; Rimareix, F.; Simon, M.; Michiels, S.; Kolb, F. |
Rituximab and dose-dense chemotherapy for adults with Burkitt's lymphoma: a randomised, controlled, open-label, phase 3 trial |
journalArticle |
2016 |
Ribrag, V.; Koscielny, S.; Bosq, J.; Leguay, T.; Casasnovas, O.; Fornecker, L. M.; Recher, C.; Ghesquieres, H.; Morschhauser, F.; Girault, S.; Le Gouill, S.; Ojeda-Uribe, M.; Mariette, C.; Cornillon, J.; Cartron, G.; Verge, V.; Chassagne-Clement, C.; Dombret, H.; Coiffier, B.; Lamy, T.; Tilly, H.; Salles, G. |
Rituximab and dose-dense chemotherapy for adults with Burkitt's lymphoma: a randomised, controlled, open-label, phase 3 trial |
journalArticle |
2016 |
Ribrag, V.; Koscielny, S.; Bosq, J.; Leguay, T.; Casasnovas, O.; Fornecker, L. M.; Recher, C.; Ghesquieres, H.; Morschhauser, F.; Girault, S.; Le Gouill, S.; Ojeda-Uribe, M.; Mariette, C.; Cornillon, J.; Cartron, G.; Verge, V.; Chassagne-Clement, C.; Dombret, H.; Coiffier, B.; Lamy, T.; Tilly, H.; Salles, G. |
Risk of Subsequent Leukemia After a Solid Tumor in Childhood: Impact of Bone Marrow Radiation Therapy and Chemotherapy |
journalArticle |
2015 |
Allodji, R. S.; Schwartz, B.; Veres, C.; Haddy, N.; Rubino, C.; Le Deley, M. C.; Labbé, M.; Diop, F.; Jackson, A.; Dayet, F.; Benabdennebi, A.; Llanas, D.; Vu Bezin, J.; Chavaudra, J.; Lefkopoulos, D.; Deutsch, E.; Oberlin, O.; de Vathaire, F.; Diallo, I. |
Revisiting vascular contraindications for transoral robotic surgery for oropharyngeal cancer |
journalArticle |
2018 |
Gorphe, P.; Auperin, A.; Honart, J. F.; Ton Van, J.; El Bedoui, S.; Bidault, F.; Temam, S.; Kolb, F.; Qassemyar, Q. |
Revisiting the definition of dose-limiting toxicities in paediatric oncology phase I clinical trials: An analysis from the Innovative Therapies for Children with Cancer Consortium |
journalArticle |
2017 |
Bautista, F.; Moreno, L.; Marshall, L.; Pearson, A. D. J.; Geoerger, B.; Paoletti, X. |
Revisiting the definition of dose-limiting toxicities in paediatric oncology phase I clinical trials: An analysis from the Innovative Therapies for Children with Cancer Consortium |
journalArticle |
2017 |
Bautista, F.; Moreno, L.; Marshall, L.; Pearson, A. D. J.; Geoerger, B.; Paoletti, X. |
Results of methotrexate-etoposide-ifosfamide based regimen (M-EI) in osteosarcoma patients included in the French OS2006/sarcome-09 study |
journalArticle |
2018 |
Gaspar, N.; Occean, B. V.; Pacquement, H.; Bompas, E.; Bouvier, C.; Brisse, H. J.; Castex, M. P.; Cheurfa, N.; Corradini, N.; Delaye, J.; Entz-Werle, N.; Gentet, J. C.; Italiano, A.; Lervat, C.; Marec-Berard, P.; Mascard, E.; Redini, F.; Saumet, L.; Schmitt, C.; Tabone, M. D.; Verite-Goulard, C.; Le Deley, M. C.; Piperno-Neumann, S.; Brugieres, L.; Sfce; Gsf, Geto; group, Unicancer sarcoma |
Results of external beam radiotherapy for diffuse choroidal hemangiomas in Sturge-Weber syndrome |
journalArticle |
2018 |
Randon, M.; Lévy-Gabriel, C.; Abbas, R.; Dendale, R.; Lumbroso, L.; Desjardins, L.; Cassoux, N. |
Results of a multicenter phase I dose-finding trial of hyperthermic intraperitoneal cisplatin after neoadjuvant chemotherapy and complete cytoreductive surgery and followed by maintenance bevacizumab in initially unresectable ovarian cancer |
journalArticle |
2016 |
Gouy, S.; Ferron, G.; Glehen, O.; Bayar, A.; Marchal, F.; Pomel, C.; Quenet, F.; Bereder, J. M.; Le Deley, M. C.; Morice, P. |
Results of a multicenter phase I dose-finding trial of hyperthermic intraperitoneal cisplatin after neoadjuvant chemotherapy and complete cytoreductive surgery and followed by maintenance bevacizumab in initially unresectable ovarian cancer |
journalArticle |
2016 |
Gouy, S.; Ferron, G.; Glehen, O.; Bayar, A.; Marchal, F.; Pomel, C.; Quenet, F.; Bereder, J. M.; Le Deley, M. C.; Morice, P. |
Results and Survival of Locally Advanced AJCC 7th Edition T4a Laryngeal Squamous Cell Carcinoma Treated with Primary Total Laryngectomy and Postoperative Radiotherapy |
journalArticle |
2016 |
Gorphe, P.; Matias, M.; Moya-Plana, A.; Tabarino, F.; Blanchard, P.; Tao, Y.; Janot, F.; Temam, S. |
Results and Survival of Locally Advanced AJCC 7th Edition T4a Laryngeal Squamous Cell Carcinoma Treated with Primary Total Laryngectomy and Postoperative Radiotherapy |
journalArticle |
2016 |
Gorphe, P.; Matias, M.; Moya-Plana, A.; Tabarino, F.; Blanchard, P.; Tao, Y.; Janot, F.; Temam, S. |
Reply to V.P. Retel et al, D. Gauchan et al, and C. Rahilly-Tierney et al |
journalArticle |
2015 |
Bonastre, J.; Marguet, S.; Lueza, B.; Michiels, S.; Delaloge, S.; Saghatchian, M. |
Reply to V.P. Retel et al, D. Gauchan et al, and C. Rahilly-Tierney et al |
journalArticle |
2015 |
Bonastre, J.; Marguet, S.; Lueza, B.; Michiels, S.; Delaloge, S.; Saghatchian, M. |
Reply to the letter to the editor 'Ablative therapies for lung metastases: a need to acknowledge the efficacy and toxicity of stereotactic ablative body radiotherapy' by Siva et al |
journalArticle |
2015 |
de Baère, T.; Aupérin, A.; Deschamps, F.; Chevallier, P.; Gaubert, Y.; Boige, V.; Fonck, M.; Escudier, B.; Palussiére, J. |
Reply to the letter to the editor 'Ablative therapies for lung metastases: a need to acknowledge the efficacy and toxicity of stereotactic ablative body radiotherapy' by Siva et al |
journalArticle |
2015 |
de Baère, T.; Aupérin, A.; Deschamps, F.; Chevallier, P.; Gaubert, Y.; Boige, V.; Fonck, M.; Escudier, B.; Palussiére, J. |
Repeated measures dose-finding design with time-trend detection in the presence of correlated toxicity data |
journalArticle |
2017 |
Yin, Jun; Paoletti, Xavier; Sargent, Daniel J; Mandrekar, Sumithra J |
Renal Cell Carcinoma Programmed Death-ligand 1, a New Direct Target of Hypoxia-inducible Factor-2 Alpha, is Regulated by von Hippel-Lindau Gene Mutation Status |
journalArticle |
2015 |
Messai, Y.; Gad, S.; Noman, M. Z.; Le Teuff, G.; Couve, S.; Janji, B.; Kammerer, S. F.; Rioux-Leclerc, N.; Hasmim, M.; Ferlicot, S.; Baud, V.; Mejean, A.; Mole, D. R.; Richard, S.; Eggermont, A. M.; Albiges, L.; Mami-Chouaib, F.; Escudier, B.; Chouaib, S. |
Renal Cell Carcinoma Programmed Death-ligand 1, a New Direct Target of Hypoxia-inducible Factor-2 Alpha, is Regulated by von Hippel-Lindau Gene Mutation Status |
journalArticle |
2015 |
Messai, Y.; Gad, S.; Noman, M. Z.; Le Teuff, G.; Couve, S.; Janji, B.; Kammerer, S. F.; Rioux-Leclerc, N.; Hasmim, M.; Ferlicot, S.; Baud, V.; Mejean, A.; Mole, D. R.; Richard, S.; Eggermont, A. M.; Albiges, L.; Mami-Chouaib, F.; Escudier, B.; Chouaib, S. |
Relationship Between Carfilzomib Dose and Efficacy Outcomes in Patients With Relapsed and/or Refractory Multiple Myeloma |
journalArticle |
2015 |
Squifflet, P.; Michiels, S.; Siegel, D.; Vij, R.; Jagannath, S.; Saad, E. D.; Rajangam, K.; Ro, S. K.; Buyse, M. |
Relationship Between Carfilzomib Dose and Efficacy Outcomes in Patients With Relapsed and/or Refractory Multiple Myeloma |
journalArticle |
2015 |
Squifflet, P.; Michiels, S.; Siegel, D.; Vij, R.; Jagannath, S.; Saad, E. D.; Rajangam, K.; Ro, S. K.; Buyse, M. |
Reduced acute toxicity and improved efficacy from intensity-modulated proton therapy (IMPT) for the management of head and neck cancer |
journalArticle |
2016 |
McKeever, M. R.; Sio, T. T.; Gunn, G. B.; Holliday, E. B.; Blanchard, P.; Kies, M. S.; Weber, R. S.; Frank, S. J. |
Reduced acute toxicity and improved efficacy from intensity-modulated proton therapy (IMPT) for the management of head and neck cancer |
journalArticle |
2016 |
McKeever, M. R.; Sio, T. T.; Gunn, G. B.; Holliday, E. B.; Blanchard, P.; Kies, M. S.; Weber, R. S.; Frank, S. J. |
REBECA: a phase I study of bevacizumab and whole-brain radiation therapy for the treatment of brain metastasis from solid tumours |
journalArticle |
2015 |
Levy, C.; Allouache, D.; Lacroix, J.; Dugue, A. E.; Supiot, S.; Campone, M.; Mahe, M.; Kichou, S.; Leheurteur, M.; Hanzen, C.; Dieras, V.; Kirova, Y.; Campana, F.; Le Rhun, E.; Gras, L.; Bachelot, T.; Sunyach, M. P.; Hrab, I.; Geffrelot, J.; Gunzer, K.; Constans, J. M.; Grellard, J. M.; Clarisse, B.; Paoletti, X. |
REBECA: a phase I study of bevacizumab and whole-brain radiation therapy for the treatment of brain metastasis from solid tumours |
journalArticle |
2015 |
Levy, C.; Allouache, D.; Lacroix, J.; Dugue, A. E.; Supiot, S.; Campone, M.; Mahe, M.; Kichou, S.; Leheurteur, M.; Hanzen, C.; Dieras, V.; Kirova, Y.; Campana, F.; Le Rhun, E.; Gras, L.; Bachelot, T.; Sunyach, M. P.; Hrab, I.; Geffrelot, J.; Gunzer, K.; Constans, J. M.; Grellard, J. M.; Clarisse, B.; Paoletti, X. |
Readressing the rationale of irradiation in stage I seminoma guidelines: a critical essay |
journalArticle |
2019 |
Berghen, C.; Albersen, M.; Blanchard, P.; Bossi, A.; Briganti, A.; Cozzarini, C.; Decaestecker, K.; Fonteyne, V.; Haustermans, K.; Joniau, S.; Lim Joon, D.; Khoo, V.; Nguyen, P. L.; Ost, P.; Villeirs, G.; Vulsteke, C.; Zietman, A.; De Meerleer, G. |
Re: Christopher J.D. Wallis, Refik Saskin, Richard Choo, et al. Surgery Versus Radiotherapy for Clinically-localized Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol 2016;70:21-30 |
journalArticle |
2016 |
Blanchard, P.; Briganti, A.; Bossi, A. |
Re: Christopher J.D. Wallis, Refik Saskin, Richard Choo, et al. Surgery Versus Radiotherapy for Clinically-localized Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol 2016;70:21-30 |
journalArticle |
2016 |
Blanchard, P.; Briganti, A.; Bossi, A. |
Randomized phase II trial comparing molecularly targeted therapy based on tumor molecular profiling versus conventional therapy in patients with refractory cancer: cross-over analysis from the SHIVA trial |
journalArticle |
2017 |
Belin, L.; Kamal, M.; Mauborgne, C.; Plancher, C.; Mulot, F.; Delord, J. P.; Gonçalves, A.; Gavoille, C.; Dubot, C.; Isambert, N.; Campone, M.; Trédan, O.; Ricci, F.; Alt, M.; Loirat, D.; Sablin, M. P.; Paoletti, X.; Servois, V.; Le Tourneau, C. |
Randomized phase II trial comparing molecularly targeted therapy based on tumor molecular profiling versus conventional therapy in patients with refractory cancer: cross-over analysis from the SHIVA trial |
journalArticle |
2017 |
Belin, L.; Kamal, M.; Mauborgne, C.; Plancher, C.; Mulot, F.; Delord, J. P.; Gonçalves, A.; Gavoille, C.; Dubot, C.; Isambert, N.; Campone, M.; Trédan, O.; Ricci, F.; Alt, M.; Loirat, D.; Sablin, M. P.; Paoletti, X.; Servois, V.; Le Tourneau, C. |